Analyst Price Target is $24.33
▲ +59.35% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Rain Therapeutics in the last 3 months. The average price target is $24.33, with a high forecast of $26.00 and a low forecast of $22.00. The average price target represents a 59.35% upside from the last price of $15.27.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Rain Therapeutics.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.